Is OEDEMA PERIPHERAL a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed OEDEMA PERIPHERAL.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 97 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported OEDEMA PERIPHERAL to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and OEDEMA PERIPHERAL. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause OEDEMA PERIPHERAL, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes OEDEMA PERIPHERAL. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if OEDEMA PERIPHERAL ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing OEDEMA PERIPHERAL: 97
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where OEDEMA PERIPHERAL is a reported side effect: 2.9138%

FDA reports of any drug causing OEDEMA PERIPHERAL : 72181
Average percentage for all medicated patients where OEDEMA PERIPHERAL is reported as a complication: 0.4524%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with OEDEMA PERIPHERAL:

ASPIRIN (7231 patients)
VIOXX (6081 patients)
FOSAMAX (5869 patients)
LASIX (4952 patients)
LYRICA (4828 patients)
HUMIRA (4457 patients)
ENBREL (3825 patients)
PREDNISONE (3674 patients)
LIPITOR (3427 patients)
FUROSEMIDE (3250 patients)
COUMADIN (3161 patients)
SYNTHROID (2946 patients)
LISINOPRIL (2911 patients)
MAGNEVIST (2827 patients)
NORVASC (2657 patients)
ZOMETA (2607 patients)
NEURONTIN (2495 patients)
METHOTREXATE (2488 patients)
NEXIUM (2488 patients)
HEPARIN SODIUM INJECTION (2449 patients)
FORTEO (2441 patients)
ATENOLOL (2305 patients)
FOLIC ACID (2255 patients)
OMEPRAZOLE (2129 patients)
HYDROCHLOROTHIAZIDE (2096 patients)
DIGOXIN (2067 patients)
CELEBREX (2060 patients)
PLAVIX (2012 patients)
POTASSIUM CHLORIDE (1912 patients)
XANAX (1898 patients)
SIMVASTATIN (1886 patients)
ALBUTEROL (1853 patients)
PROTONIX (1834 patients)
SANDOSTATIN LAR (1834 patients)
LEVOTHYROXINE SODIUM (1811 patients)
AREDIA (1802 patients)
AMBIEN (1802 patients)
PRILOSEC (1772 patients)
LEVAQUIN (1706 patients)
ZOCOR (1695 patients)
ALLOPURINOL (1664 patients)
SEROQUEL (1641 patients)
DIOVAN (1623 patients)
ACETAMINOPHEN (1620 patients)
ZOLOFT (1611 patients)
AVANDIA (1610 patients)
TOPROL-XL (1601 patients)
AVONEX (1583 patients)
YAZ (1573 patients)
REMICADE (1567 patients)
CRESTOR (1542 patients)
PREVACID (1537 patients)
OMNISCAN (1515 patients)
VITAMIN D (1514 patients)
METFORMIN HCL (1509 patients)
IBUPROFEN (1481 patients)
WARFARIN SODIUM (1471 patients)
OXYCONTIN (1470 patients)
YASMIN (1449 patients)
VICODIN (1443 patients)
GABAPENTIN (1374 patients)
PERCOCET (1373 patients)
METOPROLOL TARTRATE (1337 patients)
PREDNISONE TAB (1336 patients)
TYSABRI (1328 patients)
REVLIMID (1326 patients)
LANTUS (1296 patients)
CALCIUM (1295 patients)
AMLODIPINE (1292 patients)
GLEEVEC (1286 patients)
INSULIN (1260 patients)
PREDNISOLONE (1260 patients)
CYMBALTA (1256 patients)
ADVAIR DISKUS 100/50 (1236 patients)
ATIVAN (1212 patients)
ACTOS (1205 patients)
LEXAPRO (1202 patients)
DEXAMETHASONE (1201 patients)
COREG (1183 patients)
LORAZEPAM (1129 patients)
PAXIL (1125 patients)
PREMARIN (1105 patients)
SPIRIVA (1090 patients)
SPIRONOLACTONE (1067 patients)
SINGULAIR (1043 patients)
DECADRON (1023 patients)
MULTI-VITAMINS (1007 patients)
TRACLEER (1001 patients)
OXYCODONE HCL (997 patients)
NITROGLYCERIN (947 patients)
LORTAB (915 patients)
MORPHINE (914 patients)
ALDACTONE (913 patients)
EFFEXOR (907 patients)
EPOGEN (900 patients)
ZOFRAN (892 patients)
ALPRAZOLAM (891 patients)
MULTI-VITAMIN (888 patients)
CLONAZEPAM (887 patients)
METOPROLOL (872 patients)
GLUCOPHAGE (864 patients)
COZAAR (863 patients)
LOVENOX (849 patients)
FLEXERIL (844 patients)
AMOXICILLIN (839 patients)
ASCORBIC ACID (829 patients)
PROZAC (829 patients)
ZYRTEC (814 patients)
ALENDRONATE SODIUM (813 patients)
LOPRESSOR (808 patients)
CALCIUM CARBONATE (806 patients)
CLONIDINE (801 patients)
OPTIMARK (797 patients)
GLYBURIDE (781 patients)
ACTONEL (776 patients)
ARANESP (772 patients)
BENADRYL (765 patients)
CHANTIX (759 patients)
VALIUM (750 patients)
DURAGESIC-100 (749 patients)
AVELOX (748 patients)
TRAMADOL HCL (746 patients)
FISH OIL (746 patients)
VITAMIN B-12 (745 patients)
KLONOPIN (744 patients)
BYETTA (736 patients)
VITAMIN E (734 patients)
ALLEGRA (734 patients)
COMPAZINE (726 patients)
GLIPIZIDE (725 patients)
CELEXA (724 patients)
PRADAXA (724 patients)
NAPROXEN (718 patients)
NEXAVAR (714 patients)
ZANTAC (711 patients)
ZYPREXA (700 patients)
WELLBUTRIN (700 patients)
PROCRIT (699 patients)
ZETIA (697 patients)
DILAUDID (697 patients)
CIPROFLOXACIN (689 patients)
DIAZEPAM (688 patients)
RANITIDINE (680 patients)
POTASSIUM (673 patients)
HUMALOG (663 patients)
ALTACE (658 patients)
ENALAPRIL MALEATE (649 patients)
COLACE (644 patients)
MORPHINE SULFATE (640 patients)
RAMIPRIL (637 patients)
FLOMAX (636 patients)
FENTANYL (634 patients)
METFORMIN (629 patients)
TYLENOL (CAPLET) (629 patients)
AMARYL (625 patients)
REGLAN (623 patients)
TRAZODONE HCL (620 patients)
FERROUS SULFATE TAB (615 patients)
BACLOFEN (613 patients)
NIASPAN (611 patients)
TYLENOL (610 patients)
ARIMIDEX (608 patients)
THALIDOMIDE (602 patients)
KLOR-CON (601 patients)
LANSOPRAZOLE (598 patients)
RENAGEL (597 patients)
MULTIHANCE (596 patients)
TAXOTERE (586 patients)
CARVEDILOL (583 patients)
AMLODIPINE BESYLATE (583 patients)
FLONASE (583 patients)
AMITRIPTYLINE HCL (581 patients)
VELCADE (581 patients)
LEVOXYL (579 patients)
[THERAPY UNSPECIFIED] (577 patients)
ACCUTANE (569 patients)
BONIVA (567 patients)
PEPCID (566 patients)
PROHANCE (564 patients)
IRON (559 patients)
BEXTRA (557 patients)
FLUCONAZOLE (556 patients)
HYDROCODONE (553 patients)
EXJADE (549 patients)
ZITHROMAX (546 patients)
GADOLINIUM IN UNSPECIFIED DRUG (544 patients)
DIFLUCAN (541 patients)
ELAVIL (541 patients)
VERAPAMIL (536 patients)
NIFEDIPINE (535 patients)
VANCOMYCIN (528 patients)
HYDROCODONE BITARTRATE (526 patients)
HEPARIN (523 patients)
AMIODARONE HCL (521 patients)
PLAQUENIL (518 patients)
ACYCLOVIR (515 patients)
DILTIAZEM (513 patients)
METOPROLOL SUCCINATE (510 patients)
XELODA (503 patients)
NYSTATIN (501 patients)
CARDIZEM (501 patients)
CEPHALEXIN (498 patients)
FOSAMAX PLUS D (497 patients)
FEMARA (495 patients)
ULTRAM (495 patients)
BETASERON (495 patients)
CLARITIN (491 patients)
OXYCODONE (490 patients)
BENICAR (489 patients)
LAMICTAL (489 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about OEDEMA PERIPHERAL and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.